E. coli ETVAX

Phase 2Biologic

SScandinavian Biopharma AB

E. coli ETVAX is one of 4 biologic programs targeting Diarrheal Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diarrheal DiseaseActive, not recruiting

Diarrheal DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Diarrheal Disease

#DrugCompanyPhaseTrials

Imodium

KKenvue Brands

Approved

1 2

Albendazole.

GSK

Approved

1 3

Glutamine

Sanofi

Phase 3

—4

E. coli ETVAX

SScandinavian Biopharma AB

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrheal Disease1 trial

Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)

Completed·SScandinavian Biopharma AB·Phase 2·NCT03729219·749 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for E. coli ETVAX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E. coli ETVAX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E. coli ETVAX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Scandinavian Biopharma AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SScandinavian Biopharma AB

E. coli ETVAX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diarrheal Disease1 trial

References

Drug Info

Quick Facts

Related News